Sturge-Weber Syndrome (SWS)

Transforming the Outlook for a Rare Vascular Brain Disorder

Sturge-Weber Syndrome (SWS) is a congenital, non-inherited disorder caused by a somatic mutation in the GNAQ gene. It affects approximately 1 in 40,000 births, leading to abnormal blood vessels in the skin (port-wine birthmark), eye, and brain.

The hallmark neurological feature of SWS is intracranial calcification, which contributes directly to seizures, stroke-like episodes, migraines, glaucoma, and cognitive decline. Up to 90% of patients experience seizures, often beginning in infancy, which can be progressive and difficult to control.

No disease-modifying therapy currently exists.

ZY-001 is being developed as the first therapy to directly target the calcification process in SWS. Our goal is to reduce seizure burden, preserve behavioral and cognitive function, and slow disease progression for the SWS community.

Zy Therapeutics collaborates closely with the Sturge-Weber Foundation (SWF) and the Brain Vascular Malformation Consortium (BVMC) to advance clinical studies and scientific initiatives.